BRPI0821310A2 - Conjugados polipeptídeos-ácido nucleico e usos dos mesmos - Google Patents
Conjugados polipeptídeos-ácido nucleico e usos dos mesmosInfo
- Publication number
- BRPI0821310A2 BRPI0821310A2 BRPI0821310-0A BRPI0821310A BRPI0821310A2 BR PI0821310 A2 BRPI0821310 A2 BR PI0821310A2 BR PI0821310 A BRPI0821310 A BR PI0821310A BR PI0821310 A2 BRPI0821310 A2 BR PI0821310A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- nucleic acid
- acid conjugates
- conjugates
- nucleic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US882507P | 2007-12-20 | 2007-12-20 | |
PCT/CA2008/002269 WO2009079790A1 (en) | 2007-12-20 | 2008-12-19 | Polypeptide-nucleic acid conjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0821310A2 true BRPI0821310A2 (pt) | 2015-06-16 |
Family
ID=40800623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0821310-0A BRPI0821310A2 (pt) | 2007-12-20 | 2008-12-19 | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110039785A1 (pt) |
EP (1) | EP2235175A4 (pt) |
JP (1) | JP2011505846A (pt) |
CN (1) | CN101946001A (pt) |
AU (1) | AU2008340943A1 (pt) |
BR (1) | BRPI0821310A2 (pt) |
CA (1) | CA2709635A1 (pt) |
MX (1) | MX2010006925A (pt) |
RU (1) | RU2010129761A (pt) |
WO (1) | WO2009079790A1 (pt) |
ZA (1) | ZA201004609B (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2368941T3 (es) | 2003-01-06 | 2011-11-23 | Angiochem Inc. | Angiopep-1, compuestos relacionados y utilizaciones correspondientes. |
DE602004028930D1 (de) | 2003-04-29 | 2010-10-14 | Avi Biopharma Inc | Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen |
DK2360258T3 (en) | 2005-02-18 | 2015-01-12 | Angiochem Inc | Aprotininpolypeptider to transport a compound of blood-brain-barrier |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
SI2233156T1 (sl) | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uporaba polipeptidov aprotinina kot nosilce v farmacevtskih konjugatih |
WO2008046228A1 (en) | 2006-10-19 | 2008-04-24 | Angiochem, Inc. | Compounds for stimulating p-glycoprotein function and uses thereof |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
MX2011006685A (es) | 2008-12-17 | 2011-09-27 | Angiochem Inc | Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos. |
MX2011011023A (es) | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
RU2012103240A (ru) * | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
EP2486061A4 (en) * | 2009-10-06 | 2013-08-28 | Angiochem Inc | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS |
MX2012011515A (es) * | 2010-04-09 | 2012-11-06 | Merck Sharp & Dohme | Entidades quimicas simples novedosas y metodos de suministro de oligonucleotidos. |
BR112012026471A2 (pt) * | 2010-04-19 | 2016-11-29 | Nlife Therapeutics S L | conjugado, processo para a síntese do mesmo, método para imagem de uma célula que expressa um transportador de neurotransmissor que compreende o contato da referida célula com o conjugado, processo para preparar um comporto de fórmula (ii) e (xiv) e composto |
EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
MX2013000250A (es) * | 2010-07-02 | 2013-10-28 | Angiochem Inc | Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos. |
WO2012150960A1 (en) * | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
US20140259192A1 (en) | 2011-07-12 | 2014-09-11 | Sanofi | Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene |
HUE033746T2 (en) | 2011-08-04 | 2018-01-29 | Yeda Res & Dev | MIR-135 and compositions thereof for the treatment of therapeutic conditions associated with serotonin |
BR112014013161A2 (pt) * | 2011-12-01 | 2019-09-24 | Angiochem Inc | compostos com enzima lisossomal alvo |
RU2014126482A (ru) * | 2011-12-01 | 2016-01-27 | Ангиочем Инк. | Нацеленные соединения ферментов и их применение |
WO2013112897A1 (en) * | 2012-01-27 | 2013-08-01 | The Regents Of The University Of California | Stabilization of biomolecules using sugar polymers |
BR112014031273A2 (pt) * | 2012-06-15 | 2017-07-25 | Angiochem Inc | compostos enzima alvejados e seus usos |
WO2014026283A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
KR101445265B1 (ko) * | 2012-09-18 | 2014-09-30 | 포항공과대학교 산학협력단 | 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물 |
AU2013336581A1 (en) | 2012-10-26 | 2015-06-11 | Nlife Therapeutics, S.L. | Compositions and methods for the treatment of Parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
WO2015006641A2 (en) * | 2013-07-12 | 2015-01-15 | Georgia State University Research Foundation, Inc. | Methods and compositions for interference with dna polymerase and dna synthesis |
US10125365B2 (en) | 2014-02-05 | 2018-11-13 | Yeda Research And Development Co. Ltd. | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
CN106282118A (zh) * | 2015-06-24 | 2017-01-04 | 武汉荣实医药科技有限公司 | 阿尔兹海默症关键致病因子app的基因工程细胞株和药物筛选模型 |
WO2019037133A1 (zh) * | 2017-08-25 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 靶向沉默APP的shRNA |
WO2019079536A1 (en) * | 2017-10-18 | 2019-04-25 | Intrabio Ltd | THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS |
EP3480212B1 (en) | 2017-11-03 | 2023-09-27 | Consejo Superior De Investigaciones Científicas | Il13ralpha2 peptide and its uses |
WO2020008083A1 (es) | 2018-07-05 | 2020-01-09 | Consejo Superior De Investigaciones Científicas | Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas |
CN111208284B (zh) * | 2018-11-22 | 2021-08-24 | 北京大学 | 糖代谢标记探针、包含其的试剂盒及其应用 |
KR102320650B1 (ko) * | 2019-10-16 | 2021-11-04 | 주식회사 시선테라퓨틱스 | 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물 |
EP4277635A1 (en) * | 2021-01-18 | 2023-11-22 | Yeda Research and Development Co. Ltd | Modified mir-135, conjugated form thereof, and uses of same |
WO2022261029A2 (en) * | 2021-06-07 | 2022-12-15 | Neubase Therapeutics, Inc. | Peptide nucleic acid therapeutics for trinucleotide repeat disorders |
EP4180527A1 (en) * | 2021-11-11 | 2023-05-17 | Hangzhou Chichuang Biotechnology Co., Ltd. | Synthesis method of targeted drug ncovshrna·2ace2 |
WO2024042466A1 (en) * | 2022-08-22 | 2024-02-29 | University Of Tartu | Brain penetrating peptides and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
EP2660322A3 (en) * | 2003-04-17 | 2013-11-13 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
EP1638605B1 (en) * | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
EP1750775A2 (en) * | 2004-05-04 | 2007-02-14 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
DK2360258T3 (en) * | 2005-02-18 | 2015-01-12 | Angiochem Inc | Aprotininpolypeptider to transport a compound of blood-brain-barrier |
SI2233156T1 (sl) * | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uporaba polipeptidov aprotinina kot nosilce v farmacevtskih konjugatih |
CA2621694A1 (en) * | 2005-09-08 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Pharmaceutical compositions for delivery of ribonucleic acid to a cell |
PL2164866T3 (pl) * | 2007-05-29 | 2014-10-31 | Angiochem Inc | Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek |
-
2008
- 2008-12-19 MX MX2010006925A patent/MX2010006925A/es not_active Application Discontinuation
- 2008-12-19 CN CN2008801270674A patent/CN101946001A/zh active Pending
- 2008-12-19 WO PCT/CA2008/002269 patent/WO2009079790A1/en active Application Filing
- 2008-12-19 AU AU2008340943A patent/AU2008340943A1/en not_active Abandoned
- 2008-12-19 JP JP2010538304A patent/JP2011505846A/ja active Pending
- 2008-12-19 EP EP08865493A patent/EP2235175A4/en not_active Withdrawn
- 2008-12-19 BR BRPI0821310-0A patent/BRPI0821310A2/pt not_active IP Right Cessation
- 2008-12-19 RU RU2010129761/10A patent/RU2010129761A/ru not_active Application Discontinuation
- 2008-12-19 US US12/808,439 patent/US20110039785A1/en not_active Abandoned
- 2008-12-19 CA CA2709635A patent/CA2709635A1/en not_active Abandoned
-
2010
- 2010-06-30 ZA ZA2010/04609A patent/ZA201004609B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20110039785A1 (en) | 2011-02-17 |
CA2709635A1 (en) | 2009-07-02 |
CN101946001A (zh) | 2011-01-12 |
EP2235175A1 (en) | 2010-10-06 |
WO2009079790A1 (en) | 2009-07-02 |
AU2008340943A1 (en) | 2009-07-02 |
ZA201004609B (en) | 2011-09-28 |
JP2011505846A (ja) | 2011-03-03 |
RU2010129761A (ru) | 2012-01-27 |
EP2235175A4 (en) | 2012-04-25 |
MX2010006925A (es) | 2011-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821310A2 (pt) | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos | |
BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
BRPI0912198A2 (pt) | anticorpos anti-fn14 e usos dos mesmos | |
BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
NL300891I2 (nl) | Lotilaner en zouten daarvan | |
BR112012001260A2 (pt) | conjugados de epsilon-polilisina e o emprego dos mesmos | |
BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
BRPI0922689A2 (pt) | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos | |
BRPI0922691A2 (pt) | conjugados de leptina e análogo de leptina e usos dos mesmos | |
SMT201600335B (it) | Proteine leganti eterodimeri e loro usi | |
BRPI0923283A2 (pt) | conjugados terapêuticos de peptídeo e usos dos mesmos | |
BRPI0914682A2 (pt) | compostos de heteroarila e usos dos mesmos | |
BRPI0912225A2 (pt) | peptídeos de direcionamento lisossomais e usos dos mesmos | |
BRPI0908906A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BRPI0814599A2 (pt) | Pesticidas e usos dos mesmos | |
BRPI1013943A2 (pt) | Composto cetais e usos dos mesmos. | |
BRPI0920209A2 (pt) | conjugados de agonistas de glp-1 e usos dos mesmos | |
BRPI1014997A2 (pt) | compostos heteroarila e usos dos mesmos | |
BRPI0912480A2 (pt) | compostos de monoalquiltina de alta pureza e usos dos mesmos | |
BRPI0817269A2 (pt) | Análogos de azacitidina e usos dos mesmos | |
BRPI0913656A2 (pt) | anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos | |
BRPI1011404A2 (pt) | mutantes e usos dos mesmos | |
BR112012003709A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
BRPI0818477A2 (pt) | Dc-sign, icam-3 e lsectin porcinos e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 48/00 (2006.01), A61K 47/54 (2017.01), A61K 4 |